Advanced search
Publication Cover
Clinical, Cosmetic and Investigational Dermatology Volume 15, 2022 - Issue
Submit an article Journal homepage
102
Views
2
CrossRef citations to date
0
Altmetric
CASE SERIES

Recalcitrant Palmar-Plantar Atopic Dermatitis Successfully Treated with Dupilumab: A Case Series

Lin Deng1 Department of Dermatology, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, 310006, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0001-9574-4632View further author information
ORCID Icon,
Yingzhi Luo1 Department of Dermatology, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, 310006, People’s Republic of ChinaView further author information
,
Binyi An2 Department of Dermatology, Jinling Hospital, Nanjing Medical University, Nanjing, 210002, People’s Republic of ChinaView further author information
,
Ming Su1 Department of Dermatology, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, 310006, People’s Republic of ChinaView further author information
,
Hong Sang3 Department of Dermatology, Jinling Hospital, Medical School of Nanjing University, Nanjing, 210002, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0001-7188-6740View further author information
ORCID Icon &
Fang Liu3 Department of Dermatology, Jinling Hospital, Medical School of Nanjing University, Nanjing, 210002, People’s Republic of ChinaCorrespondence[email protected] [email protected]
ORCID Iconhttps://orcid.org/0000-0001-6961-0219View further author information
ORCID Icon
Pages 2421-2426 | Received 22 Jul 2022, Accepted 02 Nov 2022, Published online: 10 Nov 2022

References

  • Williams HC, Jburney PG, Pembroke AC, Hay RJ. The U.K. working party’s diagnostic criteria for atopic dermatitis. III. Independent hospital validation. Br J Dermatol. 1994;131(3):406–416. doi:10.1111/J.1365-2133.1994.TB08532.X
  • Barrett A, Hahn-Pedersen J, Kragh N, Evans E, Gnanasakthy A. Patient-reported outcome measures in atopic dermatitis and chronic hand eczema in adults. Patient. 2019;12(5):445–459. doi:10.1007/S40271-019-00373-Y
  • Lee GR, Maarouf M, Hendricks AK, Lee DE, Shi VY. Current and emerging therapies for hand eczema. Dermatol Ther. 2019;32(3). doi:10.1111/DTH.12840
  • Oosterhaven JAF, Romeijn GLE, Schuttelaar MLA. Dupilumab treatment of very severe refractory atopic hand eczema. JAMA Dermatol. 2018;154(8):969–970. doi:10.1001/JAMADERMATOL.2018.2027
  • Zirwas MJ. Dupilumab for hand eczema. J Am Acad Dermatol. 2018;79(1):167–169. doi:10.1016/J.JAAD.2018.02.073
  • Oosterhaven JAF, Voorberg AN, Romeijn GLE, de Bruin-Weller MS, Schuttelaar MLA. Effect of dupilumab on hand eczema in patients with atopic dermatitis: an observational study. J Dermatol. 2019;46(8):680. doi:10.1111/1346-8138.14982
  • Efficacy and safety of dupilumab chronic hands eczema refractory to highly potent topical corticosteroids - full text view - clinicaltrials.gov. Available from: https://clinicaltrials.gov/ct2/show/NCT03861455. Accessed July 6, 2022.
  • Stingeni L, Bianchi L, Antonelli E, et al. Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: a multicentre Italian real-world experience. J Eur Acad Dermatol Venereol. 2022;36(8):1292–1299. doi:10.1111/jdv.18141
  • Held E, Skoet R, Johansen JD, Agner T. The hand eczema severity index (HECSI): a scoring system for clinical assessment of hand eczema. A study of inter- and intraobserver reliability. Br J Dermatol. 2005;152(2):302–307. doi:10.1111/J.1365-2133.2004.06305.X
  • Dubin C, Del Duca E, Guttman-Yassky E. Drugs for the treatment of chronic hand eczema: successes and key challenges. Ther Clin Risk Manag. 2020;16:1319. doi:10.2147/TCRM.S292504
  • Akdis CA, Arkwright PD, Brüggen MC, et al. Type 2 immunity in the skin and lungs. Allergy. 2020;75(7):1582–1605. doi:10.1111/ALL.14318
  • Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368(26):2455–2466. doi:10.1056/NEJMOA1304048/SUPPL_FILE/NEJMOA1304048_DISCLOSURES.PDF
  • Kamata M, Tada Y, Literature A. Review of real-world effectiveness and safety of dupilumab for atopic dermatitis. JID Innov Ski Sci Mol Popul Heal. 2021;1(3):100042. doi:10.1016/J.XJIDI.2021.100042
  • Puar N, Chovatiya R, Paller AS. New treatments in atopic dermatitis. Ann Allergy Asthma Immunol. 2021;126:21–31. doi:10.1016/j.anai.2020.08.016
  • Da J, Ali K, Lu K, et al. Off-label use of dupilumab for the treatment of moderate to severe atopic dermatitis in children aged below 6 years of age: a case series. Clin Exp Dermatol. 2022;47:423–425. doi:10.1111/ced.14925

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.